SET
Reactivité: Humain, Souris, Rat
WB, FACS, ICC
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
Western blot (1-5 μg/mL). Positive Control/Tissue Expression: widely expressed. Low levels in quiescent cells duringserum starvation, contact inhibition or differentiation. Highly expressed in Wilms' tumor. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.0 mg/mL
Buffer
Phosphate buffered saline with 0.08 % Sodium Azide as preservative.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Conseil sur la manipulation
Avoid repeated freezing and thawing.
Stock
4 °C/-20 °C
Stockage commentaire
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Human SET was originally identified as part of the SET-CAN fusion gene produced by a somatic translocation event in a patient with acute undifferentiated leukemia. In developing kidney, SET is highly expressed in the zone of nephron morphogenesis. SET has been shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. SET is also involved in the regulation of renal cell proliferation and tumorigenesis. SET mRNA expression is markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. High levels of SET mRNA and SET protein expression arefound in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.Synonyms: I-2PP2A, IGAAD, Inhibitor of granzyme A-activated DNase, PHAPII, Phosphatase 2A inhibitor I2PP2A, TAF-I, Template-activating factor I